EDN1 and breast cancer: Thus, other drugs that inhibit ET-1 signaling such as empagliflozin43,44 could be considered instead of atrasentan.PerspectivesCOMPETENCY IN MEDICAL KNOWLEDGE: Although some cancer therapies have overt and/or subclinical cardiotoxic effects that increase subsequent cardiovascular risk in breast cancer patients, women with breast cancer exhibit relative cardiac remodeling and cardiac dysfunction even before chemotherapy.